PHC Corporation’s Biomedical Division has received the 2025 R&D 100 Award for LiCellMo®, a live cell metabolic pathway analyzer delivering continuous insights into cellular metabolism. Announced by R&D World, this accolade recognizes LiCellMo as one of the most revolutionary technologies introduced in the past year.
Available since late 2024 across Japan, the U.S., Europe, and Asia, LiCellMo enables researchers to monitor key metabolic pathways in real-time, ensuring more informed decision-making and improved culture quality. This helps lab managers streamline workflows and boost reproducibility in demanding research environments.
Why Lab Managers Should Take Notice
- Continuous Data Flow: Offers uninterrupted monitoring of glucose and lactate levels.
- Workflow Friendly: Integrates directly into existing CO2 incubators.
- Higher Data Integrity: Reduces contamination risk from traditional sampling.
- Supports Advanced Applications: Ideal for CGT, stem cell, and cancer immunology research.
LiCellMo builds on PHC’s proprietary in-line sensing technology, previously proven in clinical diagnostics. This innovation helps labs maintain control over culture environments, improving outcomes in both research and potential therapeutic production.
Chikara Takauo, Director of PHC Corporation and Head of the Biomedical Division, said, "We are deeply honored that LiCellMo has been recognized with an R&D 100 Award. This innovation empowers researchers with new insights into cell metabolism, particularly in cancer immunology and stem cell research, and supports the advancement of manufacturing processes for next generation therapies."
